Abstract:Background: Apolipoprotein-E ( APOE ) ε4 is a major genetic risk factor for Alzheimer's disease (AD). Current studies, which were mainly based on the clinical diagnosis rather than biomarkers, come to inconsistent conclusions regarding the associations of APOE ε4 homozygotes ( APOE ε4/ε4 ) and cerebrospinal fluid (CSF) biomarkers of AD. In addition, few studies have explored the associations of APOE ε4/ε4 with plasma biomarkers. Therefore, we aimed to investigate the associations of APOE ε4/ε4 with fluid biomarkers in dementia and biomarker-diagnosed AD. Methods: A total of 297 patients were enrolled. They were classified into Alzheimer's continuum, AD, and non-AD, according to CSF biomarkers and/or β amyloid PET results. AD was a subgroup of the AD continuum. Plasma Amyloid β (Aβ) 40, Aβ42, glial fibrillary acidic protein (GFAP), neurofilament light chain (NFL), and phosphorylated tau (P-tau)181 were quantified in 144 of the total population using an ultra-sensitive Simoa technology. We analyzed the associations of APOE ε4/ε4 on CSF and plasma biomarkers in dementia and biomarker diagnosed AD. Results: Based on the biomarker diagnostic criteria, 169 participants were diagnosed with Alzheimer's continuum and 128 individuals with non-AD, and among the former, 120 patients with AD. The APOE ε4/ε4 frequencies were 11.8% (20/169), 14.2% (17/120), and 0.8% (1/128) in Alzheimer's continuum, AD and non-AD, respectively. Only CSF Aβ42 was shown to be decreased in APOE ε4/ε4 carriers than in non-carriers for patients with AD ( p = 0.024). Furthermore, we did not find any associations of APOE ε4 with plasma biomarkers of AD and non-AD. Interestingly, we found that in non-AD patients, APOE ε4 carriers had lower CSF Aβ42 ( p = 0.018) and higher T-tau/Aβ42 ratios ( p < 0.001) and P-tau181/Aβ42 ratios ( p = 0.002) than non-carriers. Conclusion: Our data confirmed that of the three groups (AD continuum, AD, and non-AD), those with AD had the highest frequency of APOE ɛ4/ɛ4 genotypes. The APOE ɛ4/ɛ4 was associated with CSF levels of Aβ42 but not tau for AD and non-AD, suggesting that APOE ɛ4/ɛ4 affected the Aβ metabolism of both. No associations between APOE ε4/ɛ4 and plasma biomarkers of AD and non-AD were found.

APOE4 homozygosity is a new genetic form of Alzheimer's disease

The Genetic Risk Effects of APOE Ε4 and Novel Variants on Chinese Familial and Sporadic AD.

APOE α4 homozygosity — a genetic form of Alzheimer disease?

The APOE ε4 exerts differential effects on familial and other subtypes of Alzheimer's disease

APOEε4 and risk of Alzheimer's disease – time to move forward

Non-coding Variability at the APOE Locus Contributes to the Alzheimer’s Risk

Human Glia‐specific Functional Dysregulations Affected by APOE Ε4 Risk of Alzheimer's Disease

Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy

Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer’s Disease Spectrum

Alzheimer's disease phenotype based upon the carrier status of the apolipoprotein E ɛ4 allele

A multi‐hit hypothesis for an APOE4‐dependent pathophysiological state

Identification of Novel Quantitative Traits-Associated Susceptibility Loci for APOE Ε 4 Non-Carriers of Alzheimer's Disease.

Integrated genomic analysis revealed associated genes for Alzheimer's disease in APOE4 non-carriers.

Association between abnormal lipid metabolism and Alzheimer's disease: New research has revealed significant findings on the APOE4 genotype in microglia.

Advances in research of apolipoprotein E and Alzheimer's disease

Cell type-specific roles of APOE4 in Alzheimer disease

Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer’s disease pathogenesis

Exploration of Alzheimer's Disease MRI Biomarkers Using APOE4 Carrier Status in the UK Biobank

Assessing the Risk of APOE-ϵ4 on Alzheimer’s Disease Using Bayesian Additive Regression Trees

Association of APOE ε4/ε4 with fluid biomarkers in patients from the PUMCH dementia cohort

Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches